Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases | MicrobiomeTrials← Back to trialsNCT07087912
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-03-16Est. Completion: 2027-12-30
Enrollment target: 477 participants Locations- Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil
- Rheumatology Division, Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil
Other microbiome trials you might be interested in
Rheumatoid Arthritis
The study is designed to learn more about the causes of rheumatoid arthritis (RA). People who get RA have elevated prote…
Aurora, United StatesCompleted Jan 14, 2026
Rheumatoid Arthritis
Aim: To describe 1) The use of TNF blockers monotherapy in early arthritis in daily clinical practice in France 2) To ev…
Nîmes, FranceCompleted Dec 31, 2017
Aim: To describe 1) The use of TNF blockers in early arthritis in daily clinical practice in France 2) To evaluate sympt…
Multiple LocationsCompleted Dec 31, 2017